‹ Today's brief
Trial
Virus-based therapy cuts bladder-cancer recurrence by two-thirds in a phase 3 trial
In 367 patients, those given cretostimogene after surgery had 68% fewer recurrences over a median 17 months. These are the company's own topline figures, not yet peer reviewed.
The catch
Company press release with topline results only. Seventeen months is short for a cancer that recurs over years.
Sources
- globenewswire.com, GlobeNewswire (primary)
Next in today's brief
ConfirmedSpaceX catches a Starship upper stage on the tower for the first time